Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

HUMA

Humacyte Inc

Apr 10 • 04:00PM ET

0.6454

+0.0384 6.33 %

Healthcare • Biotechnology • USA • NASD

Peers: MDXG NVRO CRBP ATEC AXGN ARCT RGEN XGN MIRM ZLAB

| Held by: VTI IWM VXF VTWO IBB IWN VHT SCHA IWC IWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.21	Insider Own	15.05%	Shs Outstand	193.00M	Perf Week	0.47%
Market Cap	143.29M	Forward P/E	-	EPS next Y	-0.23	Insider Trans	0.00%	Shs Float	188.61M	Perf Month	-45.76%
Enterprise Value	157.50M	PEG	-	EPS next Q	-0.12	Inst Own	25.03%	Short Float	22.39%	Perf Quarter	-44.84%
Income	-43.21M	P/S	70.24	EPS this Y	-69.23%	Inst Trans	5.06%	Short Ratio	6.10	Perf Half Y	-61.81%
Sales	2.04M	P/B	40.06	EPS next Y	46.77%	ROA	-33.99%	Short Interest	42.22M	Perf YTD	-32.81%
Book/sh	0.02	P/C	2.83	EPS next 5Y	-	ROE	-257.38%	52W High	2.93 -77.97%	Perf Year	-58.89%
Cash/sh	0.23	P/FCF	-	EPS past 3/5Y	-30.53% 53.14%	ROIC	-65.94%	52W Low	0.55 18.01%	Perf 3Y	-80.62%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-736.46%	Volatility	9.11% 12.53%	Perf 5Y	-94.23%
Dividend TTM	-	EV/Sales	77.21	EPS Y/Y TTM	83.69%	Oper. Margin	-5306.04%	ATR (14)	0.09	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.95	Sales Y/Y TTM	-	Profit Margin	-2120.07%	RSI (14)	38.00	Recom	1.43
Dividend Gr. 3/5Y	- -	Current Ratio	3.69	EPS Q/Q	19.47%	SMA20	-17.44%	Beta	2.14	Target Price	5.07
Payout	-	Debt/Eq	20.85	Sales Q/Q	-	SMA50	-33.24%	Rel Volume	0.67	Prev Close	0.61
Employees	184	LT Debt/Eq	20.07	Earnings	Mar 27 BMO	SMA200	-55.86%	Avg Volume	6.92M	Price	0.65
IPO	Dec 01, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	1.29% -65.39%	Trades		Volume	4,654,054	Change	6.33%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-27-25	Initiated	Barclays	Overweight	$3.50
May-14-25	Resumed	H.C. Wainwright	Buy	$4
Dec-20-24	Reiterated	H.C. Wainwright	Buy	$12 → $15
Dec-11-23	Initiated	H.C. Wainwright	Buy	$6
Aug-14-23	Upgrade	Piper Sandler	Underweight → Neutral	$2.75 → $3.50
Jun-22-23	Initiated	Cantor Fitzgerald	Overweight	$6
May-16-22	Downgrade	Piper Sandler	Overweight → Underweight	$10 → $4
Oct-29-21	Initiated	Cowen	Outperform	$17
Sep-24-21	Initiated	Oppenheimer	Outperform	$16
Sep-22-21	Initiated	BTIG Research	Buy	$19
Sep-16-21	Initiated	Piper Sandler	Overweight	$17

Show Previous Ratings

Apr-09-26 03:50PM	Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders? (PR Newswire) -6.83%
Mar-27-26 07:00AM	Humacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business Update (GlobeNewswire) -13.21%
Mar-26-26 09:17AM	Humacyte Inc (HUMA) Q4 2025 Earnings Report Preview: What To Look For (GuruFocus.com) -5.42%
08:00AM	Humacyte Appoints Rick McElheny as Senior Vice President of Business Development (GlobeNewswire)
Mar-23-26 08:00AM	Humacyte To Announce 2025 Fourth Quarter and Year End Financial Results and Provide Business Update on March 27, 2026 (GlobeNewswire) +8.61%
08:31AM	Loading…
Mar-19-26 08:31AM	Humacyte Receives Symvess Purchase Commitment for Clinical Evaluation and Outreach Program in the Kingdom of Saudi Arabia (GlobeNewswire) -19.42%
08:30AM	Humacyte, Inc. Announces Pricing of $20 Million Registered Direct Offering of Common Stock (GlobeNewswire)
Mar-17-26 08:00AM	Humacyte Submits Marketing Authorization Application for Symvess in Israel for Vascular Trauma Repair (GlobeNewswire)
Mar-06-26 09:30AM	Humacyte, Inc. (HUMA) Is Considered a Good Investment by Brokers: Is That True? (Zacks)
Mar-02-26 08:00AM	Humacyte To Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-18-26 08:00AM	Humacyte Announces Presentation of Symvess Long-Term Safety and Efficacy Results at VESS Meeting (GlobeNewswire) -5.26%
Feb-10-26 06:00PM	Humacyte, Inc. (HUMA) Falls More Steeply Than Broader Market: What Investors Need to Know (Zacks) -13.93%
Feb-09-26 08:00AM	Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels (GlobeNewswire) +30.02%
Feb-02-26 06:00PM	Humacyte, Inc. (HUMA) Exceeds Market Returns: Some Facts to Consider (Zacks)
Jan-08-26 08:00AM	Humacyte Announces Hospital Charge Data Showing High Expense of Preventable Extremity Arterial Injury Complications (GlobeNewswire)
09:40AM	Loading…
Jan-07-26 09:40AM	Is Humacyte, Inc. (HUMA) Outperforming Other Medical Stocks This Year? (Zacks) +11.11%
Jan-05-26 08:00AM	Humacyte Announces Planned Marketing Authorization Application for Symvess in Israel (GlobeNewswire) +8.72%
Dec-22-25 08:00AM	Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess in Extremity Trauma Repair (GlobeNewswire)
Dec-16-25 08:00AM	Humacyte Announces Credit Facility of Up to $77.5 Million with Avenue Capital (GlobeNewswire) -5.08%
Dec-10-25 02:12PM	Humacyte (HUMA): Benchmark Remains Bullish on Stock (Insider Monkey)
Dec-05-25 09:30AM	Wall Street Analysts See Humacyte, Inc. (HUMA) as a Buy: Should You Invest? (Zacks) -5.38%
Nov-20-25 08:00AM	Humacyte Announces Presentations at VEITHsymposium Highlighting Positive Acellular Tissue Engineered Vessel (ATEV) Clinical Results (GlobeNewswire)
Nov-14-25 09:30AM	Should You Invest in Humacyte, Inc. (HUMA) Based on Bullish Wall Street Views? (Zacks)
Nov-13-25 08:00AM	Humacyte Announces Six Presentations Scheduled for the Upcoming 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITHsymposium) (GlobeNewswire)
Nov-12-25 02:03PM	Humacyte Inc (HUMA) Q3 2025 Earnings Call Highlights: Strong Symvess Sales Growth Amidst ... (GuruFocus.com)
08:30AM	Humacyte, Inc. (HUMA) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Humacyte Announces Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Nov-11-25 07:30AM	Earnings To Watch: Humacyte Inc (HUMA) Reports Q3 2025 Result (GuruFocus.com) -5.19%
Nov-10-25 08:00AM	Humacyte Announces Presentation of Positive Two-Year Results from Phase 3 Dialysis Access Trial at the American Society of Nephrology's Kidney Week 2025 (GlobeNewswire)
Nov-06-25 06:00PM	Humacyte, Inc. (HUMA) Declines More Than Market: Some Information for Investors (Zacks) -9.66%
08:00AM	Loading…
08:00AM	Humacyte to Present Third Quarter Financial Results and Provide Business Update on November 12, 2025 (GlobeNewswire)
Oct-30-25 06:00PM	Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know (Zacks)
08:00AM	Humacyte Announces Publication of New Data Comparing Symvess to Autologous Vein in Extremity Arterial Trauma (GlobeNewswire)
Oct-24-25 06:00PM	Humacyte, Inc. (HUMA) Surpasses Market Returns: Some Facts Worth Knowing (Zacks)
Oct-17-25 06:00PM	Humacyte, Inc. (HUMA) Laps the Stock Market: Here's Why (Zacks) +5.23%
Oct-14-25 06:15PM	Humacyte, Inc. (HUMA) Advances While Market Declines: Some Information for Investors (Zacks)
Oct-07-25 06:15PM	Humacyte, Inc. (HUMA) Declines More Than Market: Some Information for Investors (Zacks) -33.67%
09:00AM	Humacyte Announces Pricing of $60.0 Million Oversubscribed Registered Direct Offering (GlobeNewswire)
Oct-06-25 08:00AM	Humacyte Announces Publication of Long-Term Results for Ukrainian Patients Treated in Real-World Combat Setting with Symvess (GlobeNewswire) +18.10%
Oct-01-25 06:15PM	Humacyte, Inc. (HUMA) Outperforms Broader Market: What You Need to Know (Zacks)
Sep-29-25 08:00AM	Humacyte Announces Expansion of Intellectual Property for Pipeline Products with Granting of New U.S. Patent for Bioengineered Esophagus (GlobeNewswire)
Sep-22-25 06:15PM	Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note (Zacks)
Sep-18-25 07:00AM	Humacyte Announces Publication of Preclinical Data on Use of the CTEV as a Coronary Artery Bypass Graft (CABG) (GlobeNewswire) +16.99%
Sep-15-25 07:00AM	Humacyte Announces Publication of Outcomes for Patients with Hospital-Acquired Vascular Complications Treated with Symvess (GlobeNewswire)
Aug-20-25 09:30AM	Is It Worth Investing in Humacyte, Inc. (HUMA) Based on Wall Street's Bullish Views? (Zacks)
Aug-12-25 03:03AM	Humacyte Inc (HUMA) Q2 2025 Earnings Call Highlights: Navigating Challenges and Celebrating ... (GuruFocus.com)
Aug-11-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) -29.64%
08:15AM	Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Humacyte Announces Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Aug-07-25 08:00AM	Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 11, 2025 (GlobeNewswire) +11.76%
Aug-06-25 06:00PM	Humacyte, Inc. (HUMA) Stock Dips While Market Gains: Key Facts (Zacks)
Jul-31-25 06:00PM	Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights (Zacks) -5.00%
Jul-25-25 06:00PM	Humacyte, Inc. (HUMA) Stock Dips While Market Gains: Key Facts (Zacks) -5.24%
Jul-24-25 06:15PM	Humacyte, Inc. (HUMA) Stock Falls Amid Market Uptick: What Investors Need to Know (Zacks)
Jul-23-25 08:00AM	Humacyte Announces First Symvess Sale to Military Treatment Facility (GlobeNewswire) +18.70%
Jul-18-25 06:00PM	Humacyte, Inc. (HUMA) Dips More Than Broader Market: What You Should Know (Zacks)
Jul-15-25 06:15PM	Why Humacyte, Inc. (HUMA) Dipped More Than Broader Market Today (Zacks) -7.69%
Jul-09-25 06:15PM	Humacyte, Inc. (HUMA) Stock Declines While Market Improves: Some Information for Investors (Zacks)
Jul-08-25 08:00AM	Humacyte announces Symvess ECAT Approval from U.S. Defense Logistics Agency (GlobeNewswire) +18.98%
Jul-07-25 09:08AM	Beat the Market the Zacks Way: Humacyte, Starbucks, Oracle in Focus (Zacks) -5.26%
Jun-30-25 06:00PM	Humacyte, Inc. (HUMA) Stock Declines While Market Improves: Some Information for Investors (Zacks) +9.09%
Jun-25-25 06:15PM	Humacyte, Inc. (HUMA) Stock Moves -1.79%: What You Should Know (Zacks)
Jun-18-25 06:00PM	Humacyte, Inc. (HUMA) Gains As Market Dips: What You Should Know (Zacks)
Jun-09-25 08:00AM	Results from Humacyte's V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting (GlobeNewswire)
Jun-02-25 08:00AM	Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3 (GlobeNewswire)
May-30-25 09:30AM	Is Humacyte, Inc. (HUMA) a Buy as Wall Street Analysts Look Optimistic? (Zacks)
May-19-25 04:05PM	Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq (GlobeNewswire) +11.66%
May-13-25 08:45AM	Humacyte, Inc. (HUMA) Reports Q1 Loss, Lags Revenue Estimates (Zacks) +31.06%
07:30AM	Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-09-25 08:00AM	Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025 (GlobeNewswire)
Apr-30-25 06:00PM	Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know (Zacks)
12:00PM	All You Need to Know About Humacyte, Inc. (HUMA) Rating Upgrade to Buy (Zacks)
Apr-24-25 06:00PM	Humacyte, Inc. (HUMA) Ascends But Remains Behind Market: Some Facts to Note (Zacks)
Apr-16-25 06:15PM	Humacyte, Inc. (HUMA) Increases Despite Market Slip: Here's What You Need to Know (Zacks) +8.39%
Apr-03-25 06:00PM	Humacyte, Inc. (HUMA) Stock Moves -0.68%: What You Should Know (Zacks) -6.90%
Mar-29-25 12:05PM	Lululemon reports Q4 beat, CoreWeave IPO priced at $40: Morning Buzz (TipRanks)
10:40AM	Humacyte price target lowered to $8 from $10 at BTIG (TipRanks)
Mar-28-25 01:48PM	Humacyte, Inc. (HUMA) Q4 2024 Earnings Conference Call Transcript (Seeking Alpha)
07:30AM	Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update (GlobeNewswire)
Mar-26-25 04:28PM	Humacyte: Doubts Cast Around Efficacy Of Symvess May Be Hard To Dispel (SeekingAlpha) -30.43%
09:30AM	Brokers Suggest Investing in Humacyte, Inc. (HUMA): Read This Before Placing a Bet (Zacks)
08:00AM	Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025 (GlobeNewswire)
Mar-25-25 08:35PM	Humacyte, Inc. Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -13.40%
04:01PM	Humacyte, Inc. Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Mar-24-25 06:00PM	Humacyte, Inc. (HUMA) Flat As Market Gains: What You Should Know (Zacks)
10:42AM	Humacyte: Symvess' Approval And Launch Are Just The First Steps To Adoption (Downgrade) (SeekingAlpha)
Mar-10-25 08:00AM	Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvess (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics (GlobeNewswire) -6.15%
Mar-06-25 08:00AM	Trestle Bio Announces Research Collaboration with Humacyte (Business Wire) -6.03%
Mar-03-25 08:00AM	Humacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvess (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March 6, 2025 (GlobeNewswire) -10.15%
Feb-27-25 04:05PM	Humacyte to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
08:00AM	Humacyte Announces Issuance of U.S. Patent Covering Manufacturing of Symvess and Other Bioengineered Tissues (GlobeNewswire)
Feb-26-25 08:00AM	Humacyte Announces Commercial Launch of Symvess (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma (GlobeNewswire) +12.83%
Jan-28-25 08:00AM	Humacyte and Pluristyx Announce Gene Editing Partnership to Support BioVascular Pancreas (BVP ) Development Using iPSCs (GlobeNewswire)
Jan-21-25 08:00AM	Humacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV for Coronary Artery Bypass Grafting (GlobeNewswire)
Jan-17-25 05:14AM	Humacyte, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - HUMA (PR Newswire)
Jan-13-25 12:02PM	Humacyte, Inc. Sued for Securities Law Violations Investors Should Contact Levi and Korsinsky Before January 17, 2025 to Discuss Your Rights HUMA (GlobeNewswire)
08:00AM	Humacyte Provides Update on Commercial Launch and Pricing of Symvess (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma (GlobeNewswire)
Jan-03-25 05:30AM	Humacyte, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your Rights - HUMA (PR Newswire)
Jan-02-25 10:07AM	Humacyte, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - HUMA (PR Newswire)
Dec-24-24 08:25AM	Humacyte price target raised to $17 from $15 at Benchmark (TipRanks)

Humacyte, Inc. engages in the business of developing and manufacturing off-the-shelf, universally implantable, bioengineered human tissues, advanced tissue constructs, and organ systems with the goal of improving the lives of patients and transforming the practice of medicine. The company was founded by Laura E. Niklason, Shannon Dahl, and Juliana L. Blum on October 13, 2004 and is headquartered in Durham, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dougan Brady W	Director	Aug 19 '25	Sale	1.63	1,100,000	1,793,000	591,685	Aug 20 07:30 PM
Dougan Brady W	Director	Aug 18 '25	Sale	1.83	549,360	1,005,329	1,691,685	Aug 20 07:30 PM
Dougan Brady W	Director	Aug 20 '25	Sale	1.58	591,685	934,862	0	Aug 20 07:30 PM
Niklason Laura E	President, CEO and Director	Aug 19 '25	Sale	1.63	1,100,000	1,793,000	591,685	Aug 20 07:29 PM
Niklason Laura E	President, CEO and Director	Aug 18 '25	Sale	1.83	549,360	1,005,329	1,691,685	Aug 20 07:29 PM
Niklason Laura E	President, CEO and Director	Aug 20 '25	Sale	1.58	591,685	934,862	0	Aug 20 07:29 PM
AYABUDGE LLC	Director	Aug 20 '25	Proposed Sale	1.58	591,685	936,654		Aug 20 04:17 PM
AYABUDGE LLC	Director	Aug 19 '25	Proposed Sale	1.63	1,100,000	1,790,244		Aug 19 04:20 PM
AYABUDGE LLC	Director	Aug 18 '25	Proposed Sale	1.83	549,360	1,002,928		Aug 18 04:28 PM
Scheessele William John	Chief Commercial Officer	Apr 14 '25	Buy	1.54	6,493	9,999	22,018	Apr 15 04:03 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

HUMA

Humacyte Inc

Upgrade your Finviz experience